Worsening of motor features of Parkinsonism with olanzapine
Identifieur interne : 002F66 ( Istex/Curation ); précédent : 002F65; suivant : 002F67Worsening of motor features of Parkinsonism with olanzapine
Auteurs : Eric S. Molho [États-Unis] ; Stewart A. Factor [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 1999-11.
English descriptors
- KwdEn :
Abstract
Clozapine is the current treatment of choice for drug‐induced psychosis (DIP) occurring in Parkinson's disease. However, alternative medications have been sought because of the small but significant risk of agranulocytosis and the need for frequent blood testing. The new “atypical” antipsychotic olanzapine (OLZ) has recently been proposed as a safe and effective option for treating psychosis in this setting. To investigate this, we retrospectively evaluated all 12 of our patients treated with OLZ for DIP. Symptoms of psychosis were improved in nine of 12 patients, but nine of 12 patients also experienced worsening of motor functioning while on OLZ. The worsening was considered dramatic in six of these patients. Overall, there was no significant increase in levodopa doses on OLZ. Only one patient remained on OLZ at the time of the analysis. Nine patients were switched to alternative treatment for DIP. We conclude that although OLZ may improve symptoms of psychosis in parkinsonian patients, it can also worsen motor functioning. In some patients, the degree of motor worsening may be intolerable.
Url:
DOI: 10.1002/1531-8257(199911)14:6<1014::AID-MDS1017>3.0.CO;2-9
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002F66
Links to Exploration step
ISTEX:295A7D8B0347294665D08E59C403C706A45CC210Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Worsening of motor features of Parkinsonism with olanzapine</title><author><name sortKey="Molho, Eric S" sort="Molho, Eric S" uniqKey="Molho E" first="Eric S." last="Molho">Eric S. Molho</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Albany Medical College, Albany, New York, U.S.A.</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Albany Medical College, Albany, New York</wicri:regionArea></affiliation></author><author><name sortKey="Factor, Stewart A" sort="Factor, Stewart A" uniqKey="Factor S" first="Stewart A." last="Factor">Stewart A. Factor</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Albany Medical College, Albany, New York, U.S.A.</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Albany Medical College, Albany, New York</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:295A7D8B0347294665D08E59C403C706A45CC210</idno><date when="1999" year="1999">1999</date><idno type="doi">10.1002/1531-8257(199911)14:6<1014::AID-MDS1017>3.0.CO;2-9</idno><idno type="url">https://api.istex.fr/document/295A7D8B0347294665D08E59C403C706A45CC210/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002F66</idno><idno type="wicri:Area/Istex/Curation">002F66</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Worsening of motor features of Parkinsonism with olanzapine</title><author><name sortKey="Molho, Eric S" sort="Molho, Eric S" uniqKey="Molho E" first="Eric S." last="Molho">Eric S. Molho</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Albany Medical College, Albany, New York, U.S.A.</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Albany Medical College, Albany, New York</wicri:regionArea></affiliation></author><author><name sortKey="Factor, Stewart A" sort="Factor, Stewart A" uniqKey="Factor S" first="Stewart A." last="Factor">Stewart A. Factor</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Albany Medical College, Albany, New York, U.S.A.</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Albany Medical College, Albany, New York</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="1999-11">1999-11</date><biblScope unit="vol">14</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="1014">1014</biblScope><biblScope unit="page" to="1016">1016</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">295A7D8B0347294665D08E59C403C706A45CC210</idno><idno type="DOI">10.1002/1531-8257(199911)14:6<1014::AID-MDS1017>3.0.CO;2-9</idno><idno type="ArticleID">MDS1017</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Olanzapine</term><term>Parkinsonism</term><term>Psychosis</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Clozapine is the current treatment of choice for drug‐induced psychosis (DIP) occurring in Parkinson's disease. However, alternative medications have been sought because of the small but significant risk of agranulocytosis and the need for frequent blood testing. The new “atypical” antipsychotic olanzapine (OLZ) has recently been proposed as a safe and effective option for treating psychosis in this setting. To investigate this, we retrospectively evaluated all 12 of our patients treated with OLZ for DIP. Symptoms of psychosis were improved in nine of 12 patients, but nine of 12 patients also experienced worsening of motor functioning while on OLZ. The worsening was considered dramatic in six of these patients. Overall, there was no significant increase in levodopa doses on OLZ. Only one patient remained on OLZ at the time of the analysis. Nine patients were switched to alternative treatment for DIP. We conclude that although OLZ may improve symptoms of psychosis in parkinsonian patients, it can also worsen motor functioning. In some patients, the degree of motor worsening may be intolerable.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F66 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 002F66 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:295A7D8B0347294665D08E59C403C706A45CC210
|texte= Worsening of motor features of Parkinsonism with olanzapine
}}
| This area was generated with Dilib version V0.6.23. |  |